HRP20120549T1 - Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk - Google Patents

Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk Download PDF

Info

Publication number
HRP20120549T1
HRP20120549T1 HRP20120549AT HRP20120549T HRP20120549T1 HR P20120549 T1 HRP20120549 T1 HR P20120549T1 HR P20120549A T HRP20120549A T HR P20120549AT HR P20120549 T HRP20120549 T HR P20120549T HR P20120549 T1 HRP20120549 T1 HR P20120549T1
Authority
HR
Croatia
Prior art keywords
pyridin
hydroxy
thieno
dihydro
phenyl
Prior art date
Application number
HRP20120549AT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel@Cravo
Franck@Lepifre
Sophie@Hallakou@Bozec
Christine@Charon
Original Assignee
Merck@Patent@GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120549(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck@Patent@GmbH filed Critical Merck@Patent@GmbH
Publication of HRP20120549T1 publication Critical patent/HRP20120549T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20120549AT 2008-05-05 2009-04-08 Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk HRP20120549T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290423 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (1)

Publication Number Publication Date
HRP20120549T1 true HRP20120549T1 (hr) 2012-07-31

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120549AT HRP20120549T1 (hr) 2008-05-05 2009-04-08 Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk

Country Status (26)

Country Link
US (1) US8604202B2 (cg-RX-API-DMAC7.html)
EP (1) EP2280952B1 (cg-RX-API-DMAC7.html)
JP (1) JP5536757B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160038065A (cg-RX-API-DMAC7.html)
CN (1) CN102015676B (cg-RX-API-DMAC7.html)
AR (1) AR071530A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009243811B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910832B8 (cg-RX-API-DMAC7.html)
CA (1) CA2723429C (cg-RX-API-DMAC7.html)
CO (1) CO6331304A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113112T1 (cg-RX-API-DMAC7.html)
DK (1) DK2280952T3 (cg-RX-API-DMAC7.html)
EA (1) EA020773B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010654A (cg-RX-API-DMAC7.html)
ES (1) ES2388485T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120549T1 (cg-RX-API-DMAC7.html)
IL (1) IL208988A (cg-RX-API-DMAC7.html)
MX (1) MX2010011916A (cg-RX-API-DMAC7.html)
MY (1) MY160357A (cg-RX-API-DMAC7.html)
NZ (1) NZ589690A (cg-RX-API-DMAC7.html)
PL (1) PL2280952T3 (cg-RX-API-DMAC7.html)
PT (1) PT2280952E (cg-RX-API-DMAC7.html)
SI (1) SI2280952T1 (cg-RX-API-DMAC7.html)
UA (1) UA103617C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009135580A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201008722B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
US10308663B2 (en) 2015-06-16 2019-06-04 University Of Virginia Patent Foundation Inhibitors of PTP4A3 for the treatment of cancer
MA42456B1 (fr) 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
WO2019067442A1 (en) * 2017-09-26 2019-04-04 Ideaya Biosciences, Inc. DIHYDROTHIENO [3,2-B] PYRIDINE COMPOUNDS
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
AU2006327898A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
UA103321C2 (ru) * 2008-04-11 2013-10-10 Мерк Патент Гмбх Производные тиенопиридона как активаторы amp-активированной протеинкиназы (амрк)

Also Published As

Publication number Publication date
CA2723429A1 (en) 2009-11-12
AU2009243811B2 (en) 2014-04-10
KR101648593B1 (ko) 2016-08-16
BRPI0910832B1 (pt) 2020-09-15
CN102015676A (zh) 2011-04-13
ES2388485T3 (es) 2012-10-15
BRPI0910832B8 (pt) 2021-05-25
US20110060001A1 (en) 2011-03-10
JP2011519876A (ja) 2011-07-14
ZA201008722B (en) 2012-01-25
AR071530A1 (es) 2010-06-23
EP2280952B1 (en) 2012-06-27
KR20160038065A (ko) 2016-04-06
PT2280952E (pt) 2012-09-28
MY160357A (en) 2017-02-28
PL2280952T3 (pl) 2012-10-31
NZ589690A (en) 2012-07-27
CN102015676B (zh) 2014-05-28
UA103617C2 (ru) 2013-11-11
WO2009135580A1 (en) 2009-11-12
CA2723429C (en) 2016-10-11
JP5536757B2 (ja) 2014-07-02
IL208988A (en) 2016-02-29
US8604202B2 (en) 2013-12-10
IL208988A0 (en) 2011-01-31
EP2280952A1 (en) 2011-02-09
DK2280952T3 (da) 2012-07-23
CO6331304A2 (es) 2011-10-20
AU2009243811A1 (en) 2009-11-12
BRPI0910832A2 (pt) 2015-08-11
EA201001733A1 (ru) 2011-06-30
HK1156313A1 (en) 2012-06-08
BRPI0910832A8 (pt) 2016-07-12
EA020773B1 (ru) 2015-01-30
KR20110010757A (ko) 2011-02-07
MX2010011916A (es) 2010-11-26
CY1113112T1 (el) 2016-04-13
SI2280952T1 (sl) 2012-09-28
ECSP10010654A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
HRP20120549T1 (hr) Derivati tienopiridona kao amp aktivirani aktivatori protein kinaze ampk
JP2011519876A5 (cg-RX-API-DMAC7.html)
ES2529226T3 (es) Nuevos componentes que se unen a FXR (NR1H4) y modulan su actividad
HRP20170487T1 (hr) Spojevi koji inhibiraju djelovanje katehol-o-metil transferaze
RS53710B2 (sr) Jedinjenja kao antagonisti b1 bradikinina
CA2532067A1 (en) N-methyle-substituted benzamidazoles
Kumar et al. Iodine-catalyzed three-component one-pot synthesis of naphthopyranopyrimidines under solvent-free conditions
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
FI3738434T3 (fi) Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
HRP20161103T1 (hr) Kemijski spojevi
HRP20180176T1 (hr) Spojevi korisni u sintezi spojeva benzamida
RU2015115278A (ru) Производные гидропирролопиррола для применения в качестве ингибиторов синтазы жирных кислот
WO1994015932A1 (en) Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
HRP20151397T1 (hr) DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
AR083402A1 (es) Pirrolidinonas como inhibidores de metap-2
CA2726005C (en) Process for the preparation of halogenated benzoic acid derivatives
CN102000054B (zh) 一种黄酮类似物、制备及其作为抗糖尿病药物的用途
CA2581730A1 (en) New histone deacetylases inhibitors
ME02534B (me) Modulatori x receptora iz jetre
EG26411A (en) Catalyst for reacting carboxylic acid nitriles
ME02405B (me) Spojevi pirazola као inhibitori sglt1
JP2013536164A5 (cg-RX-API-DMAC7.html)
CN104262309B (zh) 一种色酮类衍生物及其合成方法
CN105294476B (zh) 2‑酰氧基丙烯酰胺类化合物的合成方法